| 臺大學術典藏 |
2022-01-24T09:31:06Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Hong C.-M.; Liu C.-H.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen Y.-W.; Kao J.-H.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:05Z |
Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan
|
Su H.-J.; Kao J.-H.; Tseng T.-C.; Yang H.-C.; Su T.-H.; Chen P.-J.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:03Z |
High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy
|
Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:02Z |
Clinical and histologic features of patients with biopsy-proven metabolic dysfunction-associated fatty liver disease
|
Huang S.-C.; Su H.-J.; Kao J.-H.; Tseng T.-C.; Yang H.-C.; Su T.-H.; Chen P.-J.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:02Z |
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan
|
Liu C.-H.; Su T.-H.; CHUN-JEN LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:02Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; CHUN-JEN LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:01Z |
Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents
|
Huang S.-C.; Cheng P.-N.; Liu C.-H.; Yang H.-C.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Kao J.-H.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:01Z |
Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis
|
Su T.-H.; Peng C.-Y.; Chang S.-H.; Tseng T.-C.; CHUN-JEN LIU; Chen C.-L.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:00Z |
Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment
|
Liu C.-H.; Peng C.-Y.; Kao W.-Y.; Yang S.-S.; Shih Y.-L.; Lin C.-L.; Tsai M.-K.; Lee C.-Y.; Chang C.-C.; Wu J.-H.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:59Z |
Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study
|
Papatheodoridi M.; Su T.-H.; Hadziyannis E.; Liao C.-H.; Orfanidou Α.; Yang H.-C.; Zachou K.; CHUN-JEN LIU; Kourikou A.; Gatselis N.; Manolakopoulos S.; Dalekos G.; Kao J.-H.; Hadziyannis S.; Papatheodoridis G.V. |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load
|
Tseng T.-C.; CHUN-JEN LIU; Yang W.-T.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen H.-H.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:56Z |
Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients
|
Cheng H.-R.; Yang H.-C.; Lin S.-R.; Yang T.-Y.; Lin Y.-Y.; Su T.-H.; Tseng T.-C.; CHUN-JEN LIU; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:56Z |
Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters
|
Lin S.-R.; Yang T.-Y.; Peng C.-Y.; Lin Y.-Y.; Dai C.-Y.; Wang H.-Y.; Su T.-H.; Tseng T.-C.; Liu I.-J.; Cheng H.-R.; Shen Y.-C.; Wu F.-Y.; CHUN-JEN LIU; Chen D.-S.; Chen P.-J.; Yang H.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:56Z |
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy
|
Liu C.-H.; Sun H.-Y.; Hsieh S.-M.; Liu W.-C.; Sheng W.-H.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:52Z |
Correction to: Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients (Hepatology International, (2021), 15, 3, (582-592), 10.1007/s12072-021-10186-7)
|
Cheng H.-R.; Yang H.-C.; Lin S.-R.; Yang T.-Y.; Lin Y.-Y.; Su T.-H.; Tseng T.-C.; CHUN-JEN LIU; Kao J.-H. |
| 臺大學術典藏 |
2022-01-13T08:46:00Z |
High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments
|
Nien H.-C.; Hsu S.-J.; Su T.-H.; PO-JEN YANG; Sheu J.-C.; Wang J.-T.; Chow L.-P.; Chen C.-L.; Kao J.-H.; Yang W.-S. |
| 臺大學術典藏 |
2022-01-07T06:05:52Z |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
|
Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; CHIH-YUAN LEE; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H. |
| 國立成功大學 |
2022 |
Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents
|
Huang, S.-C.;Cheng, P.-N.;Liu, C.-H.;Yang, H.-C.;Su, T.-H.;Tseng, Tseng T.-C.;Chen, P.-J.;Kao, J.-H.;Liu, C.-J. |
| 臺大學術典藏 |
2021-12-01T02:29:06Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan
|
Liu C.-H.; Liu C.-J.; CHIEN-CHING HUNG; Hsieh S.-M.; Su T.-H.; Sun H.-Y.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-10-27T03:22:18Z |
Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era
|
Cheng C.-L.; Huang S.-C.; Chen J.-H.; Wei C.-H.; Fang W.-Q.; Su T.-H.; CHANG-TSU YUAN; Liu J.-H.; Chuang M.-K.; Tien H.-F. |
| 臺大學術典藏 |
2021-09-27T05:32:39Z |
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy
|
Liu C.-H.; Sun H.-Y.; Hsieh S.-M.; Liu W.-C.; WANG-HUEI SHENG; Liu C.-J.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T06:12:40Z |
APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: More questions than answers [5]
|
Su T.-H.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:33Z |
Acute fatty liver of pregnancy with concurrent acute hepatitis B virus infection
|
Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:18Z |
Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B
|
Su T.-H.; Hsu C.-S.; Chen C.-L.; Liu C.-H.; Huang Y.-W.; Tseng T.-C.; Liu C.-J.; Chen P.-J.; Lai M.-Y.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:12:14Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; JIA-HORNG KAO; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
